Europe Narcolepsy Drugs Market

Europe Narcolepsy Drugs Market Size (2022 to 2027)

The size of the Narcolepsy Drugs Market in Europe is predicted to showcase a robust CAGR from 2022 to 2027. Narcolepsy is a neurological disorder that decreases the ability to regulate sleep cycles.

High discretionary income and growing consciousness regarding the advantages of narcolepsy drugs in the European countries are majorly accelerating the market in this region. More than 25,000 people in the UK are affected by narcolepsy, and nearly 75% of them are not treated as they are not diagnosed or incorrectly diagnosed. The rise in the cases is alarming. In Europe, the H1N1 influenza pandemic has ended in an increase in sleep-related disorders in 2009. The expected growth of sleep disorders because of unhealthy lifestyles and increment in stress levels are some factors accelerating the growth in the region.

The cost associated with the treatment and manufacturing of the drugs required for the medication impedes the market over the period. Strict rules and regulations for the approval of the drugs by the US FDA are hampering the market, and the lengthy approval process also hinders the growth. The deficit of awareness related to the diagnosis and treatment available is restraining the market.

This research report on the Europe Narcolepsy Drugs Market has been segmented & sub-segmented into the following categories:

By Type:

• Central Nervous System Stimulants
• Tricyclic Antidepressants
• Sodium Oxybyzate
• Selective Serotonin Reuptake Inhibitor
• Others

By Indication:

• Daytime Extreme Sleepiness
• Cataplexia
• Others

By Country:

• United Kingdom
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Rest of Europe

Regional Analysis:

Europe is anticipated to hold the second-largest market in narcolepsy over the period. Factors like the usability of funds for research and development of novel drugs and enormous patient count drive the market in the region. Developed economies like France, Italy, and Germany are responsible for market growth due to the surge in the number of obese people. The increasing number of people being affected by narcolepsy and the growth in the disease's severity is fueling the market growth in the region. 

The UK is dominating the European narcolepsy drugs market, accounting for holding a significant share because of the existence of many key players in addition to the appearance of the stellar healthcare system. Germany is witnessed to be the quickest growing in the region over the period. Factors responsible for the area's growth are escalating acquisition rate, increasing spending on the healthcare domain made by the government specifically in the developing economies, firmly established healthcare infrastructure, and growing research and development of new drugs. In Germany, Jazz pharmaceuticals Xyrem are the only drug approved by the US FDA for cataplexy. The pharmaceuticals have received European marketing authorization for Sunosi as one of the treatments for extreme daytime sleepiness in adults with narcolepsy and obstructive sleep apnoea.

Top companies dominating the European Narcolepsy Drugs Market profiled in this report are Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc, Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc, Bioprojet, and Graymark Healthcare, Inc.